Sara Coca Membribes, Clinical Research Fellow to Prof Powles at Barts Health NHS Trust, shared a post on X:
“Our work on KIM1 in advanced RCC is now published in European Urology. We conducted an exploratory analysis of KIM1 in pRCC and ccRCC to assess its role as a prognostic and on-treatment monitoring biomarker.
Key findings:
- Baseline KIM1 was in pRCC vs ccRCC
- baseline KIM1 in ccRCC was linked to shorter OS
- Responders showed on-treatment KIM1 in both cohorts (−59.2% in ccRCC vs −32% in pRCC)
- In ccRCC, on-treatment in KIM1 correlated with shorter PFS and OS.”
Title: KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma
Authors: Sara Coca Membribes, Wenxin Xu, Cristina Suárez, Poulam M. Patel, James Larkin, Begoña P. Valderrama, Charles Mein, Charlotte Ackermann, Thomas Powles
Read the Full Article.
Other articles featuring Sara Coca Membribes on OncoDaily.
